nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—Short period—Delavirdine—acquired immunodeficiency syndrome	0.161	0.178	CcSEcCtD
Nepafenac—Polymenorrhoea—Delavirdine—acquired immunodeficiency syndrome	0.0775	0.0854	CcSEcCtD
Nepafenac—Dry eye syndrome—Saquinavir—acquired immunodeficiency syndrome	0.0527	0.0581	CcSEcCtD
Nepafenac—Lacrimation decreased—Saquinavir—acquired immunodeficiency syndrome	0.0303	0.0334	CcSEcCtD
Nepafenac—Teratogenicity—Efavirenz—acquired immunodeficiency syndrome	0.0279	0.0307	CcSEcCtD
Nepafenac—Iritis—Nelfinavir—acquired immunodeficiency syndrome	0.0202	0.0222	CcSEcCtD
Nepafenac—Eye swelling—Indinavir—acquired immunodeficiency syndrome	0.019	0.0209	CcSEcCtD
Nepafenac—Iritis—Efavirenz—acquired immunodeficiency syndrome	0.0154	0.0169	CcSEcCtD
Nepafenac—Iritis—Ritonavir—acquired immunodeficiency syndrome	0.0136	0.015	CcSEcCtD
Nepafenac—Pregnancy—Efavirenz—acquired immunodeficiency syndrome	0.0103	0.0113	CcSEcCtD
Nepafenac—Blepharitis—Delavirdine—acquired immunodeficiency syndrome	0.00908	0.01	CcSEcCtD
Nepafenac—Blepharitis—Ritonavir—acquired immunodeficiency syndrome	0.0084	0.00925	CcSEcCtD
Nepafenac—Pregnancy—Lamivudine—acquired immunodeficiency syndrome	0.00836	0.0092	CcSEcCtD
Nepafenac—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00829	0.0999	CbGeAlD
Nepafenac—Dry eye—Didanosine—acquired immunodeficiency syndrome	0.00813	0.00895	CcSEcCtD
Nepafenac—Blepharitis—Saquinavir—acquired immunodeficiency syndrome	0.00808	0.0089	CcSEcCtD
Nepafenac—Diabetes mellitus—Amprenavir—acquired immunodeficiency syndrome	0.00806	0.00888	CcSEcCtD
Nepafenac—PTGS2—endothelium—acquired immunodeficiency syndrome	0.00792	0.0955	CbGeAlD
Nepafenac—Blood pressure increased—Nevirapine—acquired immunodeficiency syndrome	0.00792	0.00872	CcSEcCtD
Nepafenac—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.00736	0.0887	CbGeAlD
Nepafenac—Diabetes mellitus—Didanosine—acquired immunodeficiency syndrome	0.00735	0.00809	CcSEcCtD
Nepafenac—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.00703	0.0848	CbGeAlD
Nepafenac—Diabetes mellitus—Nelfinavir—acquired immunodeficiency syndrome	0.0064	0.00705	CcSEcCtD
Nepafenac—Diabetes mellitus—Stavudine—acquired immunodeficiency syndrome	0.00638	0.00702	CcSEcCtD
Nepafenac—Photophobia—Zidovudine—acquired immunodeficiency syndrome	0.00624	0.00687	CcSEcCtD
Nepafenac—Eye irritation—Saquinavir—acquired immunodeficiency syndrome	0.00582	0.00641	CcSEcCtD
Nepafenac—Arthritis—Nelfinavir—acquired immunodeficiency syndrome	0.00573	0.00631	CcSEcCtD
Nepafenac—Photophobia—Delavirdine—acquired immunodeficiency syndrome	0.00524	0.00577	CcSEcCtD
Nepafenac—Dry eye—Delavirdine—acquired immunodeficiency syndrome	0.00516	0.00568	CcSEcCtD
Nepafenac—Diabetes mellitus—Indinavir—acquired immunodeficiency syndrome	0.00516	0.00568	CcSEcCtD
Nepafenac—Eye pain—Indinavir—acquired immunodeficiency syndrome	0.00497	0.00547	CcSEcCtD
Nepafenac—Photophobia—Ritonavir—acquired immunodeficiency syndrome	0.00485	0.00534	CcSEcCtD
Nepafenac—Dry eye—Saquinavir—acquired immunodeficiency syndrome	0.00459	0.00506	CcSEcCtD
Nepafenac—Photophobia—Lamivudine—acquired immunodeficiency syndrome	0.00445	0.0049	CcSEcCtD
Nepafenac—Diabetes mellitus—Ritonavir—acquired immunodeficiency syndrome	0.00431	0.00475	CcSEcCtD
Nepafenac—Arthritis—Delavirdine—acquired immunodeficiency syndrome	0.00417	0.00459	CcSEcCtD
Nepafenac—Eye pain—Ritonavir—acquired immunodeficiency syndrome	0.00415	0.00457	CcSEcCtD
Nepafenac—Diabetes mellitus—Saquinavir—acquired immunodeficiency syndrome	0.00415	0.00457	CcSEcCtD
Nepafenac—Sinusitis—Nelfinavir—acquired immunodeficiency syndrome	0.00402	0.00443	CcSEcCtD
Nepafenac—Sinusitis—Stavudine—acquired immunodeficiency syndrome	0.00401	0.00442	CcSEcCtD
Nepafenac—Arthritis—Ritonavir—acquired immunodeficiency syndrome	0.00386	0.00425	CcSEcCtD
Nepafenac—Arthritis—Saquinavir—acquired immunodeficiency syndrome	0.00371	0.00409	CcSEcCtD
Nepafenac—Eye disorder—Nelfinavir—acquired immunodeficiency syndrome	0.0036	0.00396	CcSEcCtD
Nepafenac—Immune system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00359	0.00395	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00357	0.00393	CcSEcCtD
Nepafenac—PTGS1—skin of body—acquired immunodeficiency syndrome	0.00354	0.0426	CbGeAlD
Nepafenac—Angiopathy—Nelfinavir—acquired immunodeficiency syndrome	0.00349	0.00385	CcSEcCtD
Nepafenac—Sinusitis—Zidovudine—acquired immunodeficiency syndrome	0.00349	0.00384	CcSEcCtD
Nepafenac—Immune system disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00348	0.00383	CcSEcCtD
Nepafenac—Immune system disorder—Abacavir—acquired immunodeficiency syndrome	0.00342	0.00376	CcSEcCtD
Nepafenac—PTGS2—skin of body—acquired immunodeficiency syndrome	0.00338	0.0408	CbGeAlD
Nepafenac—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00338	0.00372	CcSEcCtD
Nepafenac—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00335	0.00369	CcSEcCtD
Nepafenac—Sinusitis—Indinavir—acquired immunodeficiency syndrome	0.00324	0.00357	CcSEcCtD
Nepafenac—Dry mouth—Didanosine—acquired immunodeficiency syndrome	0.0032	0.00353	CcSEcCtD
Nepafenac—Sinusitis—Efavirenz—acquired immunodeficiency syndrome	0.00306	0.00337	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00297	0.00328	CcSEcCtD
Nepafenac—Sinusitis—Delavirdine—acquired immunodeficiency syndrome	0.00293	0.00323	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00293	0.00322	CcSEcCtD
Nepafenac—Magnesium salicylate—ALB—acquired immunodeficiency syndrome	0.00285	0.315	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00283	0.00312	CcSEcCtD
Nepafenac—PTGS1—digestive system—acquired immunodeficiency syndrome	0.00283	0.0341	CbGeAlD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00282	0.00311	CcSEcCtD
Nepafenac—Immune system disorder—Indinavir—acquired immunodeficiency syndrome	0.0028	0.00309	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.00278	0.00306	CcSEcCtD
Nepafenac—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.00278	0.00306	CcSEcCtD
Nepafenac—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00277	0.00305	CcSEcCtD
Nepafenac—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00274	0.00302	CcSEcCtD
Nepafenac—Eye disorder—Efavirenz—acquired immunodeficiency syndrome	0.00274	0.00302	CcSEcCtD
Nepafenac—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.00274	0.033	CbGeAlD
Nepafenac—Sinusitis—Ritonavir—acquired immunodeficiency syndrome	0.00271	0.00299	CcSEcCtD
Nepafenac—PTGS2—digestive system—acquired immunodeficiency syndrome	0.0027	0.0326	CbGeAlD
Nepafenac—PTGS1—blood—acquired immunodeficiency syndrome	0.0027	0.0325	CbGeAlD
Nepafenac—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00267	0.00294	CcSEcCtD
Nepafenac—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.00266	0.00293	CcSEcCtD
Nepafenac—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00266	0.00293	CcSEcCtD
Nepafenac—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00265	0.00292	CcSEcCtD
Nepafenac—Immune system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00265	0.00292	CcSEcCtD
Nepafenac—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00263	0.0029	CcSEcCtD
Nepafenac—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00261	0.00287	CcSEcCtD
Nepafenac—Sinusitis—Saquinavir—acquired immunodeficiency syndrome	0.00261	0.00287	CcSEcCtD
Nepafenac—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.0026	0.0313	CbGeAlD
Nepafenac—PTGS2—blood—acquired immunodeficiency syndrome	0.00258	0.0311	CbGeAlD
Nepafenac—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.00255	0.0028	CcSEcCtD
Nepafenac—PTGS1—vagina—acquired immunodeficiency syndrome	0.0025	0.0301	CbGeAlD
Nepafenac—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.00249	0.0301	CbGeAlD
Nepafenac—Sinusitis—Lamivudine—acquired immunodeficiency syndrome	0.00249	0.00274	CcSEcCtD
Nepafenac—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.00248	0.0299	CbGeAlD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00246	0.0027	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00244	0.00269	CcSEcCtD
Nepafenac—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00244	0.00268	CcSEcCtD
Nepafenac—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.00242	0.00267	CcSEcCtD
Nepafenac—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.0024	0.00265	CcSEcCtD
Nepafenac—PTGS2—vagina—acquired immunodeficiency syndrome	0.00239	0.0288	CbGeAlD
Nepafenac—PTGS1—lung—acquired immunodeficiency syndrome	0.00236	0.0285	CbGeAlD
Nepafenac—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00236	0.0026	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.00235	0.00259	CcSEcCtD
Nepafenac—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.00235	0.00259	CcSEcCtD
Nepafenac—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00234	0.00258	CcSEcCtD
Nepafenac—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.00233	0.00257	CcSEcCtD
Nepafenac—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00232	0.00256	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.00232	0.00255	CcSEcCtD
Nepafenac—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00231	0.00255	CcSEcCtD
Nepafenac—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.0023	0.00254	CcSEcCtD
Nepafenac—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.0023	0.00253	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00228	0.00251	CcSEcCtD
Nepafenac—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.00226	0.00249	CcSEcCtD
Nepafenac—PTGS2—lung—acquired immunodeficiency syndrome	0.00226	0.0272	CbGeAlD
Nepafenac—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00225	0.00248	CcSEcCtD
Nepafenac—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.00225	0.00248	CcSEcCtD
Nepafenac—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00222	0.00245	CcSEcCtD
Nepafenac—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.0022	0.00243	CcSEcCtD
Nepafenac—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00219	0.00241	CcSEcCtD
Nepafenac—PTGS1—nervous system—acquired immunodeficiency syndrome	0.00219	0.0264	CbGeAlD
Nepafenac—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00216	0.00238	CcSEcCtD
Nepafenac—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00216	0.00238	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00216	0.00238	CcSEcCtD
Nepafenac—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00215	0.00237	CcSEcCtD
Nepafenac—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00214	0.00236	CcSEcCtD
Nepafenac—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00213	0.00234	CcSEcCtD
Nepafenac—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00212	0.00234	CcSEcCtD
Nepafenac—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00211	0.00232	CcSEcCtD
Nepafenac—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.00211	0.0254	CbGeAlD
Nepafenac—PTGS2—nervous system—acquired immunodeficiency syndrome	0.00209	0.0252	CbGeAlD
Nepafenac—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00208	0.00229	CcSEcCtD
Nepafenac—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00205	0.00225	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00205	0.00225	CcSEcCtD
Nepafenac—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00204	0.00225	CcSEcCtD
Nepafenac—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00203	0.00224	CcSEcCtD
Nepafenac—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00202	0.00223	CcSEcCtD
Nepafenac—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00202	0.00222	CcSEcCtD
Nepafenac—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.00201	0.0243	CbGeAlD
Nepafenac—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00201	0.00221	CcSEcCtD
Nepafenac—Fenoprofen—ALB—acquired immunodeficiency syndrome	0.002	0.221	CrCbGaD
Nepafenac—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.002	0.0022	CcSEcCtD
Nepafenac—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.002	0.0022	CcSEcCtD
Nepafenac—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00198	0.00218	CcSEcCtD
Nepafenac—Headache—Didanosine—acquired immunodeficiency syndrome	0.00197	0.00217	CcSEcCtD
Nepafenac—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00195	0.00215	CcSEcCtD
Nepafenac—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00194	0.00213	CcSEcCtD
Nepafenac—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00194	0.00213	CcSEcCtD
Nepafenac—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00193	0.00212	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00191	0.0021	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.0019	0.0021	CcSEcCtD
Nepafenac—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.0019	0.00209	CcSEcCtD
Nepafenac—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00188	0.00207	CcSEcCtD
Nepafenac—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00188	0.00207	CcSEcCtD
Nepafenac—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00187	0.00205	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00184	0.00202	CcSEcCtD
Nepafenac—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00181	0.00199	CcSEcCtD
Nepafenac—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00181	0.00199	CcSEcCtD
Nepafenac—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00181	0.00199	CcSEcCtD
Nepafenac—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.0018	0.00199	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.0018	0.00198	CcSEcCtD
Nepafenac—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.0018	0.00198	CcSEcCtD
Nepafenac—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.00179	0.00197	CcSEcCtD
Nepafenac—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00178	0.00196	CcSEcCtD
Nepafenac—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00177	0.00195	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00175	0.00193	CcSEcCtD
Nepafenac—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00174	0.00192	CcSEcCtD
Nepafenac—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00174	0.00192	CcSEcCtD
Nepafenac—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00173	0.00191	CcSEcCtD
Nepafenac—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00173	0.0019	CcSEcCtD
Nepafenac—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00172	0.0019	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00172	0.00189	CcSEcCtD
Nepafenac—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00171	0.00189	CcSEcCtD
Nepafenac—Headache—Stavudine—acquired immunodeficiency syndrome	0.00171	0.00188	CcSEcCtD
Nepafenac—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00171	0.00188	CcSEcCtD
Nepafenac—Headache—Abacavir—acquired immunodeficiency syndrome	0.00168	0.00185	CcSEcCtD
Nepafenac—Oxcarbazepine—ALB—acquired immunodeficiency syndrome	0.00168	0.186	CrCbGaD
Nepafenac—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00168	0.00185	CcSEcCtD
Nepafenac—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00168	0.00185	CcSEcCtD
Nepafenac—PTGS1—brain—acquired immunodeficiency syndrome	0.00167	0.0202	CbGeAlD
Nepafenac—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00166	0.00183	CcSEcCtD
Nepafenac—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00164	0.00181	CcSEcCtD
Nepafenac—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00162	0.00179	CcSEcCtD
Nepafenac—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00162	0.00179	CcSEcCtD
Nepafenac—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00162	0.00178	CcSEcCtD
Nepafenac—PTGS1—lymph node—acquired immunodeficiency syndrome	0.00162	0.0195	CbGeAlD
Nepafenac—PTGS2—brain—acquired immunodeficiency syndrome	0.0016	0.0193	CbGeAlD
Nepafenac—Nausea—Abacavir—acquired immunodeficiency syndrome	0.0016	0.00176	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00159	0.00175	CcSEcCtD
Nepafenac—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00157	0.00173	CcSEcCtD
Nepafenac—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00156	0.00172	CcSEcCtD
Nepafenac—PTGS2—lymph node—acquired immunodeficiency syndrome	0.00154	0.0186	CbGeAlD
Nepafenac—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00153	0.00169	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00153	0.00169	CcSEcCtD
Nepafenac—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00151	0.00166	CcSEcCtD
Nepafenac—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00148	0.00164	CcSEcCtD
Nepafenac—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00147	0.00162	CcSEcCtD
Nepafenac—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00147	0.00162	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00146	0.00161	CcSEcCtD
Nepafenac—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00146	0.00161	CcSEcCtD
Nepafenac—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00141	0.00155	CcSEcCtD
Nepafenac—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00141	0.00155	CcSEcCtD
Nepafenac—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.0014	0.00154	CcSEcCtD
Nepafenac—Headache—Indinavir—acquired immunodeficiency syndrome	0.00138	0.00152	CcSEcCtD
Nepafenac—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00138	0.00152	CcSEcCtD
Nepafenac—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00136	0.0015	CcSEcCtD
Nepafenac—Diclofenac—ALB—acquired immunodeficiency syndrome	0.00134	0.147	CrCbGaD
Nepafenac—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00132	0.00146	CcSEcCtD
Nepafenac—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00132	0.00145	CcSEcCtD
Nepafenac—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00131	0.00144	CcSEcCtD
Nepafenac—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00131	0.00144	CcSEcCtD
Nepafenac—Headache—Efavirenz—acquired immunodeficiency syndrome	0.0013	0.00144	CcSEcCtD
Nepafenac—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.0013	0.00144	CcSEcCtD
Nepafenac—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00127	0.0014	CcSEcCtD
Nepafenac—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00125	0.00138	CcSEcCtD
Nepafenac—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00125	0.00137	CcSEcCtD
Nepafenac—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00125	0.00137	CcSEcCtD
Nepafenac—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00124	0.00136	CcSEcCtD
Nepafenac—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00122	0.00134	CcSEcCtD
Nepafenac—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.0012	0.00132	CcSEcCtD
Nepafenac—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.0013	CcSEcCtD
Nepafenac—Ketoprofen—ALB—acquired immunodeficiency syndrome	0.00118	0.131	CrCbGaD
Nepafenac—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00117	0.00129	CcSEcCtD
Nepafenac—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00117	0.00129	CcSEcCtD
Nepafenac—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00115	0.00127	CcSEcCtD
Nepafenac—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.00124	CcSEcCtD
Nepafenac—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00112	0.00123	CcSEcCtD
Nepafenac—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00111	0.00122	CcSEcCtD
Nepafenac—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00121	CcSEcCtD
Nepafenac—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00108	0.00118	CcSEcCtD
Nepafenac—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00106	0.00117	CcSEcCtD
Nepafenac—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.00116	CcSEcCtD
Nepafenac—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.001	0.00111	CcSEcCtD
